As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

The oxygen gets taken up by the body and the blood cycles back to the heart. When all things are working well, the blood ...

Each year, 500 to 1,000 people in the U.S. are diagnosed with pulmonary arterial hypertension (PAH), a progressive and often under-detected disease. To address the significant impact of this disease ...

Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant ...

Authors of a recent review shared expert insights and tips for conducting cardiac catheterization procedures to diagnose ...

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

"The financing we concluded in October was a transformational moment for Inhibikase, and positioned us to advance IkT-001Pro ...

Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung ...

Liquidia Technologies ( (LQDA) ) has released its Q3 earnings. Here is a breakdown of the information Liquidia Technologies presented to its ...

Jason Gerberry, an analyst from Bank of America Securities, reiterated the Buy rating on Liquidia Technologies (LQDA – Research Report).

Diastolic dysfunction was defined by abnormal diastolic parameters on echocardiography, with HFpEF diagnosis established by ...